8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Crimean-Congo Haemorrhagic Fever Vaccine (CCHFVaccine)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2022,
Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary researc ...
Voir le projet
15
Participants partenaires
TERMINÉ
Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria (MultiViVax)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Plasmodium vivax is the most widespread malaria and constitutes a significant proportion of human malaria cases. P. vivax accounts for 100-400 million clinical cases each year among the 2.5 billion people living at risk in Latin America, Oceania and Asia. The recently revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria and calls for a vaccine intervention ...
Voir le projet
9
Participants partenaires
TERMINÉ
Optimizing a deployable high efficacy malaria vaccine (OptiMalVax)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in ...
Voir le projet
17
Participants partenaires
TERMINÉ
RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research (RD-CONNECT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,
Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts have little interoperability and almost no systematic connection between detailed clinical and genetic information, biomaterial availability or research/trial datasets. By developing robust mechanisms and standards for linking and exploiting these data, RD-Con ...
Voir le projet
30
Participants partenaires
TERMINÉ
Food-based solutions for Optimal vitamin D Nutrition and health through the life cycle (ODIN)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Vitamin D deficiency has significant implications for human health and impacts on healthy growth and development and successful aging. Fundamental knowledge gaps are barriers to implementing a safe and effective public health strategy to prevent vitamin D deficiency and optimize status. ODIN will provide the evidence to prevent vitamin D deficiency in Europe and improve nutrition and public health ...
Voir le projet
32
Participants partenaires
TERMINÉ
Global Research in Paediatrics (GRiP)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2017,
Paediatric drugs (PD) lack appropriate testing. Most drugs have inadequate information about dosing regimen, dose adjustment and how to administer them. These are longstanding problems that unquestionably require concerted efforts at the international level. Both the US and the EU have introduced paediatric legislation that facilitates participation of children in research and pharmaceutical innov ...
Voir le projet
24
Participants partenaires
TERMINÉ
Cooperation on Chernobyl health research – CO-CHER (CO-CHER)
Date du début: 1 févr. 2014, Date de fin: 31 juil. 2016,
The IARC previously led an EU funded project “Agenda for Research on Chernobyl Health (ARCH)”, the objective of which was to recommend a strategic health research agenda following the Chernobyl accident. The ARCH demonstrated that Chernobyl provides a unique opportunity to answer questions about radiation risks. The multidisciplinary group of experts strongly supported the need for well-designed a ...
Voir le projet
8
Participants partenaires
TERMINÉ
Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,
"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Voir le projet